产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 生物制品 生化原料药 Bivalirudin

Bivalirudin

2026-10-31

产品详情

Bivalirudin
肽类
128270-60-0
中国药典,美国药典,欧洲药典,企业标准
注射级
Bivalirudin/=PTCA/=PCI
否
As per requirement
As per requirement
10克
capacity >10,000 grams
2weeks-4weeks
中国,北美洲,东欧,亚洲,中东
无

产品描述

Bivalirudin, sold under the brand names Angiomax and Angiox, among others, is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin, found in the saliva of the medicinal leech Hirudo medicinalis. It is manufactured by The Medicines Company.

Bivalirudin lacks many of the limitations seen with indirect thrombin inhibitors, such as heparin. A short, synthetic peptide, it is a potent and highly specific inhibitor of thrombin that inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for heparin-induced thrombocytopenia or heparin-induced thrombosis-thrombocytopenia syndrome. It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non–ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in seven major randomized trials. Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.

苏州法默赛科技有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

以“关爱生命、健康至上、可负担的API”为使命,我们希望与您携手合作,实现共赢,共同促进健康生活。 我司主要产品包括 司美格鲁肽、替尔泊肽、利拉鲁肽、依替巴肽、加尼瑞克、醋酸格拉替雷、特利加压素乙酸盐、奥曲肽乙酸盐、催产素乙酸盐、去氨加压素、亮丙瑞林、醋酸西曲瑞克、醋酸卡贝缩宫素、醋酸阿托西班、利那洛肽。
业务类型:
成立日期:
年营业额:
主营产品类别: